[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsclc-diagnosed-by-histology-or-cytology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsclc-diagnosed-by-histology-or-cytology":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100634003",false,"NCT07534033","Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer","Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIB-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Histologically confirmed newly diagnosed patients\n2. ECOG performance status 0-1\n3. Age ≥18 years\n4. Measurable lesions (RECIST v1.1)\n5. Organ function meeting the requirements for chemotherapy and immunotherapy.\n\nExclusion Criteria:\n\n1. Including active autoimmune diseases\n2. Recent use of immunosuppressants\n3. Interstitial lung disease\n4. Presence of other malignancies\n5. History of immunotherapy\n6. Active infection\n7. Pregnancy or drug allergies",true,"ALL","18 Years","80 Years",{"count":20,"type":21},46,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include:\n\nCan LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment?\n\nParticipants will:\n\nTake LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions",[27,28,29,30],"NSCLC Diagnosed by Histology or Cytology","A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection","Overall Lung Function is Adequate for the Planned Lung Resection","AJCC is Classified as IB-IIIC",[32,33,34],"NSCLC","IB-IIIC stage","Resectable NSCLC","RECRUITING","2026-04-13",{"date":38,"type":39},"2026-04-16","ACTUAL",{"date":41,"type":39},"2025-12-06",{"date":43,"type":21},"2027-12-23",{"name":45,"class":46},"Zhujiang Hospital","OTHER",""]